Posted by Michael Wonder on 29 Jun 2017
Final NICE nod for Sanofi’s Gaucher therapy
29 June 2017 - Sanofi’s Cerdelga can now be funded on the NHS in England and Wales to treat type 1 Gaucher disease, after cost regulators issued final guidance backing ‘routine’ use of the therapy.
It is estimated that there are around 250 people in England and Wales living with the disease, of which up 100 could be eligible for treatment as per Cerdelga’s (eliglustat) license, that is for long-term treatment in adults who are cytochrome P450 2D6 poor, intermediate or extensive metabolisers.
